Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)

aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

(2017) Richard G. Gray et al.   JOURNAL OF CLINICAL ONCOLOGY

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

(2016) Marco Colleoni et al.   JOURNAL OF CLINICAL ONCOLOGY

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

(2016) Paul E. Goss et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence

(2015) E.J. Blok et al.   CANCER TREATMENT REVIEWS

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

(2015)   LANCET

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

(2015) Jack Cuzick et al.   LANCET ONCOLOGY

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

(2015) Rinath Jeselsohn et al.   Nature Reviews Clinical Oncology

Emergence of Constitutively Active Estrogen Receptor-  Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer

(2014) R. Jeselsohn et al.   CLINICAL CANCER RESEARCH

Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis

(2014) Mustafa Al-Mubarak et al.   PLoS One

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

(2013) Jack Cuzick et al.   LANCET

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction

(2012) Rakhshanda Layeequr Rahman et al.   Cancers

High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial

(2011) D.B.Y. Fontein et al.   EJSO

Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover

(2011) Huan Jin et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

(2011) Cornelis JH van de Velde et al.   LANCET

Exemestane for Breast-Cancer Prevention in Postmenopausal Women

(2011) Paul E. Goss et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17

(2008) J. N. Ingle et al.   ANNALS OF ONCOLOGY